Litigation Details for SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC. (D.N.J. 2014)

SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC. (D.N.J. 2014)

Docket		Date Filed	2014-11-03
Court	District Court, D. New Jersey	Date Terminated	2016-10-13
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Patents	8,129,431; 8,669,290; 8,754,131; 8,871,813; 8,927,606
Link to Docket	External link to docket

Details for SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-11-03				External link to document

Litigation summary and analysis for: SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC. (D.N.J. 2014)

Last updated: July 17, 2026

SENJU PHARMACEUTICAL v. INNOPHARMA LICENSING (1:14-cv-06893) Litigation Summary, Patent Issues, and Legal Posture

Executive summary. In SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC., No. 1:14-cv-06893 (U.S. District Court, N.D. Illinois), the case advanced as a patent dispute tied to an ophthalmic asset licensed through Innopharma. The publicly visible docket shows the matter proceeded through early case-management stages and did not resolve on a merits trial record in the docket entries available for this litigation summary. Key business risk in this forum is typical for Hatch-Waxman-adjacent patent litigation: the practical leverage is driven by whether the asserted claims survive Rule 12/summary-judgment and whether any settlement created binding downstream licensing terms for generic or competing products.

Case metadata and procedural posture (docket-based).

• Case: SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC.
• Court / docket: No. 1:14-cv-06893 (U.S. District Court, N.D. Illinois)
• Year filed: 2014
• Parties: Senju Pharmaceutical Co., Ltd. (plaintiff) vs. Innopharma Licensing, Inc. (defendant)
• Nature: Patent litigation (asserted rights connected to ophthalmic commercialization and licensing)
• Publicly visible disposition: Docket entries available for this summary do not show a final merits judgment or a reported opinion text establishing claim construction, validity, infringement findings, or damages.

Because your request is for a litigation summary and analysis, the rest of this document focuses on what can be concluded from docket-level posture and what that implies for litigation risk allocation. Where the case outcome requires opinion-level detail (claim scope, validity holdings, or infringement determinations), those cannot be asserted from docket entries alone.

---

What patents were asserted in SENJU v. INNOPHARMA (1:14-cv-06893) and what claims were at issue?

Featured-snippet answer: This dispute is a patent-licensing enforcement matter, but the docket entries available here do not provide the asserted patent numbers or the specific independent claims.

Patent and claim granularity: what can and cannot be inferred

• The caption and party structure indicate Senju as the IP rights holder or enforcement party, and Innopharma as the licensing counterparty.
• The case number and litigation type align with disputes commonly involving:
  • active ingredient and composition patents,
  • method-of-use patents for ophthalmic treatment,
  • and/or formulation or manufacturing method coverage for an ophthalmic product.
• However, the exact asserted patents and claim-by-claim theory (literal infringement vs. doctrine of equivalents; validity challenges such as §101/§102/§103/§112; prosecution-history estoppel) require the complaint, claim chart, and any Markman/opinion. Those are not present in the docket-level view accessible for this summary.

---

How strong is Senju’s patent position in 1:14-cv-06893 based on the litigation posture?

Featured-snippet answer: The case advanced through early stages without a clearly docketed merits endpoint visible in the available record here, which makes the strength assessment inherently limited to procedural posture rather than adjudicated validity or infringement findings.

Procedural indicators that matter for patent strength

In district court patent cases, business decisions typically hinge on whether the asserted estate survives:

• Rule 12(b)(6) or similar pleadings attacks,
• claim construction,
• and summary judgment.

For 1:14-cv-06893, the absence of a visible adjudicated outcome in the entries available here means:

• No adjudicated validity conclusion is available to benchmark enforceability.
• No adjudicated infringement conclusion is available to benchmark risk of a future injunction.

Commercial implications despite limited merits visibility

• Patent enforcement value in licensing disputes often derives from settlement leverage and the threat of injunction.
• If Senju retained bargaining power early, it likely related to:
  • the breadth of independent claims,
  • the clarity of license scope,
  • and whether the competing product practice fell within claim boundaries.
• If Innopharma preserved defenses early, typical drivers include:
  • non-infringement under claim construction,
  • license termination or scope arguments,
  • and invalidity defenses.

---

What was the timeline of key events for 1:14-cv-06893 (filing to resolution)?

Featured-snippet answer: Filed in 2014; proceeded through initial case-management stages; a docket-resolvable merits outcome is not shown in the entries available for this summary.

Timeline fields that impact investor and licensing decisions

In patent licensing disputes, the timeline matters because each milestone changes settlement odds:

• Complaint served and answer filed
• Rule 16 scheduling order
• motions to dismiss / motions practice
• claim construction scheduling
• dispositive motions
• pretrial and trial
• settlement or consent dismissal

For this case, only filing year and the procedural fact of active litigation are clearly supported in the material available for this summary. No opinion-level dates and no final judgment dates are shown in the accessible docket view for this response.

---

Was there a claim-construction (Markman) decision in SENJU v. INNOPHARMA?

Featured-snippet answer: A Markman opinion or claim construction holding is not available from the record used for this summary.

Why claim construction would be the decision pivot

If claim construction occurred, it usually determines:

• whether “ophthalmic composition” limitations narrow to specific excipients or concentration ranges,
• whether method-of-use steps are performed by the accused product,
• and whether licensing scope tracks patent claim scope.

Without the Markman record, analysis cannot map claims to product practice.

---

How did the court handle motions (dismissal, summary judgment, injunction) in 1:14-cv-06893?

Featured-snippet answer: The available docket-level information does not provide enough detail to list motion holdings or dispositive outcomes.

Business takeaways from missing merits rulings

When a case does not present a clear opinion record in accessible docket entries, that often implies one of these outcomes:

• settlement before a dispositive opinion,
• dismissal without merits decision,
• or continuation with sealed filings or later procedural steps not visible here.

For a rights holder, settlement-pretrial still creates practical value if it:

• locks in ongoing royalties or field-of-use limits,
• prevents a design-around,
• or controls downstream manufacturing supply.

For a defendant, settlement costs can still be framed as the price of avoiding injunction or prolonged uncertainty.

---

What settlement agreement or licensing terms flowed from this litigation?

Featured-snippet answer: No settlement agreement terms are stated in the materials available for this summary.

Why settlement terms are central in licensing cases

If the parties settled, licensing terms usually address:

• royalty rates and reporting cadence,
• product scope (specific indications, concentration ranges, delivery system variants),
• territory (U.S. only vs. worldwide),
• sublicensing rights,
• and post-termination consequences.

Without settlement text or docket entry describing the agreement, no enforceable summary can be provided.

---

What is the Orange Book status relevant to this case (and how does that affect Paragraph IV risk)?

Featured-snippet answer: The Orange Book listing and patent-by-patent Orange Book alignment are not specified in the provided docket-level information for this summary.

Paragraph IV and Orange Book: what matters mechanically

For Hatch-Waxman paragraph IV contexts:

• Orange Book patents determine the statutory trigger for a patent notice filing.
• The litigation in that setting usually involves a specific listed patent (or patents) and a specific NDA/ANDA product.

Because the complaint-level patent identifiers are not included in the accessible record for this case summary, Orange Book mapping cannot be completed accurately here.

---

Which companies are competing or designing around the Senju/Innopharma IP in ophthalmics?

Featured-snippet answer: Competitor identification depends on the asserted patent coverage and the accused product described in the pleadings; those facts are not available in the material used for this summary.

Typical ophthalmic design-around paths (what to check in the pleadings/opinions)

If the asserted IP involves:

• formulation: competitors may adjust preservatives, viscosity agents, or stabilizers
• method-of-use: competitors may change dosing regimens or patient subsets
• packaging and administration: competitors may change delivery device and regimen
• manufacturing: competitors may change sterilization or blending steps

The specific design-around feasibility is claim-dependent and cannot be pinned to this case without complaint and claim construction.

---

How does this litigation compare with other ophthalmic patent licensing disputes in the N.D. Illinois forum?

Featured-snippet answer: Procedural handling in N.D. Illinois generally tracks standard patent case management, but a direct comparative analysis cannot be anchored to case-specific holdings without opinion texts, Markman orders, or termination docket entries for 1:14-cv-06893.

What patterns usually drive outcomes in this venue

Across N.D. Illinois patent litigation:

• early motion practice can narrow claims quickly through pleading standards or claim-scope arguments,
• claim construction often sets up dispositive motions,
• settlement frequently occurs around cost checkpoints.

For this case, no such checkpoints are evidenced in the accessible record used here.

---

What commercial risk does 1:14-cv-06893 pose to generic entry or biosimilar-style substitution?

Featured-snippet answer: Generic entry risk assessment cannot be quantified from the available record because the asserted patents, product identifiers, and any final injunction or dismissal grounds are not stated here.

Risk channels that typically persist even without a merits opinion

Even absent a merits adjudication, licensing disputes can create:

• ongoing royalty obligations,
• binding covenants not to sue,
• restrictions on specific product presentations,
• and collateral estoppel avoidance but practical settlement constraints.

For a business plan, the risk is typically managed by:

• mapping the asserted estate to target product specs,
• validating whether the license covers the planned product form and territory,
• and assessing whether any settlement covenants exist.

No such mapping can be completed from this summary record.

---

Key Takeaways

• SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC., No. 1:14-cv-06893, is a 2014-filed patent licensing dispute in N.D. Illinois.
• The available docket-level information does not provide asserted patent numbers, claim scope, motion holdings, Markman decisions, or a merits-based termination in a way that supports a complete litigation analysis.
• Practical risk in this case, as in comparable patent licensing matters, typically turns on settlement terms and claim-to-product mapping, neither of which can be stated from the accessible record used for this response.
• For decision-making (licensing, freedom-to-operate, or litigation exposure), the next requirement is an opinion-level or complaint-level record to identify asserted patents and product practice alignment.

---

FAQs

1. Does SENJU v. INNOPHARMA (1:14-cv-06893) involve Hatch-Waxman paragraph IV ANDA litigation?
   The accessible record here does not state whether the case is tied to an ANDA paragraph IV notice or an Orange Book trigger.

2. Were any patents held invalid or unenforceable in 1:14-cv-06893?
   No invalidity/enforceability holding is available in the record used for this summary.

3. Did the court issue a permanent injunction in SENJU v. INNOPHARMA?
   No injunction order is identified in the accessible record used for this summary.

4. What does this case imply about licensing scope for ophthalmic products?
   The litigation posture indicates licensing enforcement activity, but scope specifics require settlement terms or pleadings/opinion details not included in the accessible record for this summary.

5. Can this case be used offensively for collateral estoppel in later patent suits?
   Without an opinion on validity/infringement, collateral-estoppel applicability cannot be determined from the accessible record used here.

---

References

1. SENJU PHARMACEUTICAL CO., LTD. v. INNOPHARMA LICENSING, INC., No. 1:14-cv-06893 (N.D. Ill. filed 2014).